AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an module that enables in-line analysis of blood plasma from whole blood samples; AQC Module, an in-line optical analysis of particle suspensions for quality control or monitoring applications; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company has collaboration agreement with global life science company to develop cell therapy. AcouSort AB and Bio-ReCell Ltd. announced that the two companies have signed a Letter of Intent to jointly develop a system for automated clean-up and isolation of stem cells and immune cells from adipose tissue. AcouSort AB (publ) was founded in 2010 and is based in Lund, Sweden.
Swedish Market Performance
7D7 Days: -2.9%
3M3 Months: 2.3%
1Y1 Year: 2.0%
YTDYear to Date: -1.6%
Over the last 7 days, the market has dropped 2.9%, driven by losses in every sector, especially the Industrials sector. In the last 12 months the market has been flat overall. As for the next few years, earnings are expected to grow by 17% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.